Literature DB >> 3522457

Cyclosporin A in nephrotic syndrome of childhood--a 14 month experience.

G Capodicasa, N G De Santo, F Nuzzi, C Giordano.   

Abstract

Cyclosporin A (CsA) in combination with 6-methylprednisolone was administered over a six-month period to 10 children with nephrotic syndrome (6 frequently relapsing and 4 steroid resistant) at a dose providing blood CsA concentrations of 200-400 ng/ml. In frequent relapsers 6-methylprednisolone was given initially at a dose of 60 mg/m2/day and subsequently at a dose of 35 mg/m2/48 h. In steroid resistant cases the steroid was given at an initial dose of 1 mg/kg tapering to 0.35 mg/kg by the end of the first month and to 0.22 mg/kg by the fourth month being also administered at the same dosage during the fifth and the sixth month. Among the frequent relapsers there were 30 relapsers in 116 months before CsA and 1 relapse during 70 months after CsA (in 5 patients urine was protein free and 1 relapsed after 7 months. Two of the steroid resistant cases healed. There was a modest incidence of CsA toxicity as evidenced by the usual clinical monitoring and by evaluation of creatinine clearance, plasma potassium and evolution of renal parenchymal cells as studied in the course of sequential fine needle aspiration biopsies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3522457

Source DB:  PubMed          Journal:  Int J Pediatr Nephrol        ISSN: 0391-6510


  20 in total

Review 1.  Modern management of nephrotic syndrome.

Authors:  K K Kher; S P Makker; M Sweet
Journal:  Indian J Pediatr       Date:  1988 Jul-Aug       Impact factor: 1.967

Review 2.  Treatment with cyclosporin of patients with idiopathic nephrotic syndrome.

Authors:  A Meyrier
Journal:  Springer Semin Immunopathol       Date:  1987

3.  Ciclosporin treatment in children with steroid-dependent nephrotic syndrome.

Authors:  Y Kitano; N Yoshikawa; R Tanaka; H Nakamura; M Ninomiya; H Ito
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

Review 4.  Immunosuppressive therapy in the nephrotic syndrome in children.

Authors:  R S Trompeter
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

5.  Minimal change disease with IgM+ immunofluorescence: a subtype of nephrotic syndrome.

Authors:  Sarah J Swartz; Karen W Eldin; M John Hicks; Daniel I Feig
Journal:  Pediatr Nephrol       Date:  2009-02-14       Impact factor: 3.714

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Cyclosporin A treatment in children with minimal change nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  J Brodehl; M Brandis; U Helmchen; P F Hoyer; R Burghard; J H Ehrich; R B Zimmerhackl; W Klein; K Wonigeit
Journal:  Klin Wochenschr       Date:  1988-11-15

8.  Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology.

Authors:  P Niaudet
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

9.  Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood.

Authors:  S A Hulton; T J Neuhaus; M J Dillon; T M Barratt
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

10.  Beneficial effect of second courses of cytotoxic therapy in children with minimal change nephrotic syndrome.

Authors:  D P Jones; F B Stapleton; S Roy; R J Wyatt
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.